Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.
about
CD95 promotes tumour growthThe cancer stem cell: evidence for its origin as an injured autoreactive T cellAssociation of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studiesTumor-shed PGE(2) impairs IL2Rgammac-signaling to inhibit CD4 T cell survival: regulation by theaflavins.Human FasL gene is a target of β-catenin/T-cell factor pathway and complex FasL haplotypes alter promoter functions.Apoptosis and its clinical impact.Fas receptor-mediated apoptosis: a clinical application?IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanismWhole tumor antigen vaccines.Clinicopathological significance of Fas and Fas ligand expressions in esophageal cancer.FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer.The tumour microenvironment and implications for cancer immunotherapy.Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation.Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects.Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patientsEffector CD8+CD45RO-CD27-T cells have signalling defects in patients with squamous cell carcinoma of the head and neck.Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2.The role of death receptor ligands in shaping tumor microenvironment.A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.Spontaneous apoptosis of tumor-specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancerThe impact of T-cell immunity on ovarian cancer outcomes.Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives.Recovery of zeta-chain expression and changes in spontaneous IL-10 production after PSA-based vaccines in patients with prostate cancerInterleukin 10-expressing B cells inhibit tumor-infiltrating T cell function and correlate with T cell Tim-3 expression in renal cell carcinoma.Expression of functional Fas ligand in choriocarcinoma.Nonlymphoid cultured cells possess a system controlling cellular compatibility.Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression.Apoptosis-resistant mitochondria in T cells selected for resistance to Fas signaling.Differentiation of promyelocytic leukaemia: alterations in Fas (CD95/Apo-1) and Fas ligand (CD178) expression.Increase in tumour-infiltrating lymphocytes with regulatory T cell immunophenotypes and reduced zeta-chain expression in nasopharyngeal carcinoma patients.Immunosuppression in renal cancer: differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes.Expression of the signal transduction molecule zeta in peripheral and tumour-associated lymphocytes in Hodgkin's disease in relation to the Epstein-Barr virus status of the tumour cells.Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer.Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression.Augmentation of T-cell immune responses and signal transduction proteins in oral cancer patients: potential for IL-2-mediated immunotherapy.
P2860
Q24602589-FE9DB004-9475-4D1E-BDE3-9CE7384F3DB6Q25256839-E3B66E5F-2414-475C-AC07-4CFFE3BBDC83Q26859155-E2210910-D49C-44F2-81F0-5C5CD55D7E8EQ33509284-502CA168-37FE-40A5-A31C-12CDE3A2D5BCQ34056050-3272413E-7625-4E71-9845-C377AD41FDC2Q34214558-AC6027BD-1BE4-4135-8032-5DDFA4C70C07Q34495634-6928B588-196D-4177-A36B-3E7DD3C1A3F8Q34825943-FA45E1C3-857A-446B-85A8-CBEFBECD7AD1Q35058235-A961D9A1-838E-4E5B-A34A-A75A15D5F2C7Q36250686-256BB8F0-2BB2-4444-B3D6-433B2A19E9A8Q36403535-E6AD12FB-9F5C-4297-90E7-D2D7EB66AD30Q36521830-087C8146-6F36-4D1E-9FAC-A2A9F83F7DADQ36611112-3ADA3578-7785-457A-8313-6F8537223A3AQ36616153-EBC294ED-8A78-4348-AE4E-12942187A6B7Q36622390-63C57BD0-DFF5-47DF-B30D-CAF330DF0DFAQ36648706-EB46D175-E060-4A1B-98DD-BAB666AB8FBEQ36648740-B5448CD8-7C38-4569-901C-9190DC88ABCAQ36693120-19924EC8-9FBE-4843-91F2-D7631C80DA43Q36958112-B222D283-27C7-4018-9E3E-B3DD1308F830Q37040545-65E5CE22-1D0E-4C11-B518-8B99C04A6751Q37118142-92A661CB-E8C4-4AE4-AB34-379CF5CD6C14Q37118164-2A8E1185-E27C-4D83-ABB0-744E2A60CDEFQ38281731-675EA4F8-01D1-483E-A9BC-BDA9EF912621Q40160532-902E488D-D3B5-49E7-88EC-F3D6F468D951Q40679133-870724EC-5805-4485-A499-56126F479E07Q40875486-55D0DE2D-A2F3-4C70-A1FC-EB7A3EE151D9Q42066713-A39246F0-42C9-42AB-A0B7-36834F754BF3Q43509302-B165D44A-A2ED-4EA2-A54A-93AE07713BFEQ43936447-9803D926-184C-4479-8337-F976C11D7E6CQ44638209-75FBA90A-7B29-4F11-A83A-3DD374E5031CQ45217743-B5D21573-0797-4C8C-A738-646B0F92D7CCQ45733374-7227320E-FB0A-42E3-91AF-0B0F10E0E301Q46249825-46BC8AB3-14F1-43C5-A037-B09614AD9A13Q53762262-73820ACF-2EF1-431D-8220-685890B977AFQ54570356-83FECB35-6AF0-42A7-986D-00299C44D76C
P2860
Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 1998
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lymphocyte apoptosis induced b ...... tumor-associated lymphocytes.
@en
Lymphocyte apoptosis induced b ...... tumor-associated lymphocytes.
@nl
type
label
Lymphocyte apoptosis induced b ...... tumor-associated lymphocytes.
@en
Lymphocyte apoptosis induced b ...... tumor-associated lymphocytes.
@nl
prefLabel
Lymphocyte apoptosis induced b ...... tumor-associated lymphocytes.
@en
Lymphocyte apoptosis induced b ...... tumor-associated lymphocytes.
@nl
P2093
P2860
P356
P1476
Lymphocyte apoptosis induced b ...... tumor-associated lymphocytes.
@en
P2093
Gastman BR
Rabinowich H
Reichert TE
Whiteside TL
P2860
P304
P356
10.1172/JCI1518
P407
P577
1998-06-01T00:00:00Z